Stay updated on Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.

Latest updates to the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedFooter updated to Revision: v3.4.2 and prior notice Revision: v3.4.1 removed; these are editorial changes that do not affect study information or site functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check17 days agoChange DetectedAdded a government funding lapse notice and open-status disclaimer; Updated the site revision to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check24 days agoChange Detected- UI tweaks: add 'Show glossary' option, switch to 'Last Update Submitted that Met QC Criteria' label, and update footer to 'No FEAR Act Data' and 'Revision: v3.4.0' while removing the older 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' labels.SummaryDifference0.2%

- Check38 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to the study details, eligibility criteria, or results.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a Locations section showing Illinois as a study site and updated to revision v3.3.3. Removed the HHS Vulnerability Disclosure and Illinois Locations entries (revision v3.3.2).SummaryDifference0.2%

- Check88 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. This is a minor metadata change with no impact on study content or user actions.SummaryDifference0.1%

Stay in the know with updates to Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.